Outset Medical, Inc.
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
OM$4.22+2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(25,783) | $(39,944) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 2,977 | 8,203 |
| Depreciation and amortization | 1,294 | 1,460 |
| Non-cash lease expense | 381 | 346 |
| Non-cash interest expense | 636 | 607 |
| Amortization of premium on investments, net | (402) | (1,577) |
| Provision for inventories | (74) | 450 |
| Allowance for credit losses | 197 | (1) |
| Loss on extinguishment of term loan | 7,685 | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (1,467) | (3,497) |
| Inventories | 3,691 | (6,981) |
| Prepaid expenses and other assets | (341) | (400) |
| Accounts payable | (2,772) | 945 |
| Accrued compensation and related benefits | (8,579) | (4,462) |
| Accrued expenses and other current liabilities | (370) | (1,367) |
| Accrued warranty liability | (8) | (512) |
| Deferred revenue | 396 | 1,197 |
| Operating lease liabilities | (429) | (379) |
| Accrued interest | (2,695) | — |
| Net cash used in operating activities | (25,663) | (45,912) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (123) | (354) |
| Purchases of investment securities | (96,331) | (98,652) |
| Sales and maturities of investment securities | 18,375 | 39,975 |
| Net cash used in investing activities | (78,079) | (59,031) |
| Cash flows from financing activities: | ||
| Proceeds from stock option exercises and ESPP purchases | 408 | 2,086 |
| Proceeds from issuance of term loans, net of issuance costs | 98,270 | 66,524 |
| Repayment of term loan and extinguishment costs | (204,954) | — |
| Proceeds from issuance of Series A convertible preferred stock, net of issuance costs | 161,932 | — |
| Net cash provided by financing activities | 55,656 | 68,610 |
| Net decrease in cash, cash equivalents and restricted cash | (48,086) | (36,333) |
| Cash, cash equivalents and restricted cash as of beginning of period | 127,343 | 71,838 |
| Cash, cash equivalents and restricted cash as of end of period | $79,257 | $35,505 |
| Summary of cash, cash equivalents and restricted cash reported within the balance sheets: | ||
| Cash and cash equivalents | $75,928 | $32,176 |
| Restricted cash | 3,329 | 3,329 |
| Total cash, cash equivalents and restricted cash | $79,257 | $35,505 |
| Supplemental cash flow disclosures: | ||
| Cash paid for income taxes | $108 | $256 |
| Cash paid for interest | $7,364 | $4,924 |
| Cash paid for amounts included in the measurement of operating lease liabilities | $429 | $379 |
Condensed Statements of Cash Flows
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Supplemental non-cash investing and financing activities: | ||
| Capital expenditures included in accounts payable and accrued expenses | $14 | $37 |
| Transfer of inventories to property and equipment | $— | $93 |
| Issuance costs included in accrued expenses | $300 | $— |
| Fair value of common stock warrant | $4,367 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.